Effect of dapiprazole, an alpha-adrenergic blocking agent, on aqueous humor dynamics in pigmentary glaucoma. 1996

L Mastropasqua, and P Carpineto, and M Ciancaglini, and L Lobefalo, and C Costagliola, and P E Gallenga
Institute of Ophthalmology, University G. D Annunzio, Chieti, Italy.

OBJECTIVE In this investigation the authors studied the effect of dapiprazole, an alpha-adrenergic blocking agent, on aqueous humor dynamics in patients affected with pigmentary glaucoma. METHODS Dapiprazole 0.5% eye drops were administered 3 times daily as adjunctive therapy to 16 pigmentary glaucoma patients in addition to timolol 0.5% eye drops twice daily. Computerized tonography was performed before and 3, 12 and 36 months after dapiprazole treatment. Sixteen sex- and age-matched pigmentary glaucoma patients treated with timolol 0.5% eye drops alone were used as a control group. RESULTS After 36 months of follow-up, the dapiprazole-treated group showed a significant increase in total outflow facility (C, from 0.17 +/- 0.04 to 0.22 +/- 0.07 ml min-1 mm Hg-1; p = 0.010, paired t test) and Po/C ratio (Q) significantly decreased from 113.39 +/- 31.02 to 89.22 +/- 51.66 (p = 0.036, paired t test). CONCLUSIONS Our results show that the introduction of dapiprazole in the therapy of pigmentary glaucoma may be useful in the long-term management of these patients. Its mechanism of action is likely to be due to iridoplegia; in fact, a decrease in the shedding of pigment occurs, with time, the outflow facility increases and the pigment clearance from the trabecular meshwork is enhanced.

UI MeSH Term Description Entries
D007429 Intraocular Pressure The pressure of the fluids in the eye. Ocular Tension,Intraocular Pressures,Ocular Tensions,Pressure, Intraocular,Pressures, Intraocular,Tension, Ocular,Tensions, Ocular
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009883 Ophthalmic Solutions Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. Eye Drop,Eyedrop,Eyedrops,Ophthalmic Solution,Eye Drops,Drop, Eye,Drops, Eye,Solution, Ophthalmic,Solutions, Ophthalmic
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005902 Glaucoma, Open-Angle Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris. Glaucoma Simplex,Glaucoma, Pigmentary,Glaucoma, Simple,Open-Angle Glaucoma,Chronic Primary Open Angle Glaucoma,Glaucoma, Compensated,Glaucoma, Compensative,Glaucoma, Open Angle,Glaucoma, Primary Open Angle,Glaucoma, Secondary Open Angle,Primary Open Angle Glaucoma,Secondary Open Angle Glaucoma,Compensated Glaucoma,Compensative Glaucoma,Open Angle Glaucoma,Open Angle Glaucomas,Open-Angle Glaucomas,Pigmentary Glaucoma,Simple Glaucoma,Simplex, Glaucoma,Simplices, Glaucoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L Mastropasqua, and P Carpineto, and M Ciancaglini, and L Lobefalo, and C Costagliola, and P E Gallenga
June 1956, A.M.A. archives of ophthalmology,
L Mastropasqua, and P Carpineto, and M Ciancaglini, and L Lobefalo, and C Costagliola, and P E Gallenga
January 1983, Nippon Ganka Gakkai zasshi,
L Mastropasqua, and P Carpineto, and M Ciancaglini, and L Lobefalo, and C Costagliola, and P E Gallenga
December 1980, Nippon Ganka Gakkai zasshi,
L Mastropasqua, and P Carpineto, and M Ciancaglini, and L Lobefalo, and C Costagliola, and P E Gallenga
October 1980, Nippon Ganka Gakkai zasshi,
L Mastropasqua, and P Carpineto, and M Ciancaglini, and L Lobefalo, and C Costagliola, and P E Gallenga
March 1968, Nippon Ganka Gakkai zasshi,
L Mastropasqua, and P Carpineto, and M Ciancaglini, and L Lobefalo, and C Costagliola, and P E Gallenga
September 1981, Pharmacological reviews,
L Mastropasqua, and P Carpineto, and M Ciancaglini, and L Lobefalo, and C Costagliola, and P E Gallenga
April 1967, Experientia,
L Mastropasqua, and P Carpineto, and M Ciancaglini, and L Lobefalo, and C Costagliola, and P E Gallenga
April 1998, Investigative ophthalmology & visual science,
L Mastropasqua, and P Carpineto, and M Ciancaglini, and L Lobefalo, and C Costagliola, and P E Gallenga
April 1983, Life sciences,
L Mastropasqua, and P Carpineto, and M Ciancaglini, and L Lobefalo, and C Costagliola, and P E Gallenga
April 2005, Current opinion in ophthalmology,
Copied contents to your clipboard!